Literature DB >> 1423296

Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line.

T Esaki1, S Nakano, T Tatsumoto, M Kuroki-Migita, K Mitsugi, M Nakamura, Y Niho.   

Abstract

To elucidate the mechanism of the synergistic cytotoxicity of 5-fluorouracil (5-FU) and cis-diamminedichloroplatinum(II) (CDDP), we studied the interaction of these agents using a human squamous carcinoma cell line (HST-1). Exposure to 5-FU for 24 h and to CDDP for 1 h produced a 50% inhibitory concentration of 1.0 micrograms/ml (7.7 microM) and 2.5 micrograms/ml (8.3 microM), respectively. The cytotoxic action of CDDP was augmented, and a greater than additive effect was observed when the cells were exposed to 5-FU (1.0 micrograms/ml; 7.7 microM) for 24 h before the CDDP treatment. This synergistic activity was maximal when the interval between 5-FU and CDDP exceeded 24 h. In contrast, the cytotoxicity of CDDP was attenuated when it preceded the exposure to 5-FU. Thymidine did not alter the 5-FU-CDDP interaction. Evaluation of the kinetics of the removal of DNA interstrand cross-links, measured by alkaline elution, showed a significant reduction of this removal in the cells exposed to 5-FU followed by CDDP with a drug-free interval of 48 h, as compared with cells exposed to CDDP alone, or to 5-FU immediately followed by CDDP, although no differences were found in the formation of DNA interstrand cross-links by CDDP among these cells. No significant differences in the accumulation of intracellular platinum were detected by atomic absorption spectrophotometry. These findings suggest that 5-FU modulates the repair of platinum-DNA adducts, thereby potentiating the antitumor activity of CDDP.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1423296

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Effect of cisplatin in advanced colorectal cancer resistant to 5-fluorouracil plus (S)-leucovorin.

Authors:  A Cassano; C Pozzo; D C Corsi; T Fontana; M R Noviello; A Astone; C Barone
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

2.  The synergism between Belotecan and cisplatin in gastric cancer.

Authors:  Joo Young Jung; Sang Hyun Song; Tae-Young Kim; Jung Hyun Park; Hyun-Soon Jong; Seock-Ah Im; Tae-You Kim; Yung-Jue Bang; Noe Kyoung Kim
Journal:  Cancer Res Treat       Date:  2006-09-30       Impact factor: 4.679

Review 3.  Cell, tissue and organ culture as in vitro models to study the biology of squamous cell carcinomas of the head and neck.

Authors:  P G Sacks
Journal:  Cancer Metastasis Rev       Date:  1996-03       Impact factor: 9.264

4.  Efficacy of a continuous venous infusion of fluorouracil and daily divided dose cisplatin as adjuvant therapy in resectable colorectal cancer: a prospective randomized trial.

Authors:  Fumitake Hata; Kazuaki Sasaki; Koichi Hirata; Susumu Yamamitsu; Tetsuhiko Shirasaka
Journal:  Surg Today       Date:  2008-07-09       Impact factor: 2.549

5.  Infusional 5-fluorouracil and cisplatin as first-line chemotherapy in patients with carcinoma of unknown primary site.

Authors:  Hitoshi Kusaba; Yoshihiro Shibata; Shuji Arita; Hiroshi Ariyama; Eishi Baba; Kenji Mitsugi; Mine Harada; Shuji Nakano
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

6.  A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.

Authors:  Y Segawa; H Ueoka; K Kiura; H Kamei; M Tabata; K Sakae; Y Hiraki; S Kawahara; K Eguchi; S Hiraki; M Harada
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

7.  Synergistic induction of ICAM-1 expression by cisplatin and 5-fluorouracil in a cancer cell line via a NF-kappaB independent pathway.

Authors:  K Takizawa; R Kamijo; D Ito; M Hatori; K Sumitani; M Nagumo
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

8.  Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial.

Authors:  Tetsuji Terazawa; Shunsuke Kondo; Hiroko Hosoi; Chigusa Morizane; Satoshi Shimizu; Shuichi Mitsunaga; Masafumi Ikeda; Hideki Ueno; Takuji Okusaka
Journal:  BMC Cancer       Date:  2014-04-30       Impact factor: 4.430

9.  Phase I/II study of daily carboplatin, 5-fluorouracil and concurrent radiation therapy for locally advanced non-small-cell lung cancer.

Authors:  H Yoshizawa; J Tanaka; H Kagamu; Y Maruyama; H Miyao; K Ito; T Sato; A Iwashima; E Suzuki; F Gejyo
Journal:  Br J Cancer       Date:  2003-09-01       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.